Gilead to Present New Trodelvy® Data at IASLC 2024 World Lung Cancer Conference
05 Sep 2024 //
BUSINESSWIRE
Merck to Present New Data on 10 Medicines at ESMO Congress 2024
04 Sep 2024 //
BUSINESSWIRE
EU Approves Merck`s KEYTRUDA and Padcev for Urothelial Carcinoma
03 Sep 2024 //
BUSINESSWIRE
BeyondSpring Presents Plinabulin Data at Lung Cancer Conference and ESMO 2024
03 Sep 2024 //
GLOBENEWSWIRE
IO Biotech Updates On Pivotal Phase 3 Trial Of IO102-IO103 With Keytruda
30 Aug 2024 //
GLOBENEWSWIRE
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
29 Aug 2024 //
BUSINESSWIRE
EC Approves Astellas` PADCEV With KEYTRUDA For Advanced Urothelial Cancer
27 Aug 2024 //
PR NEWSWIRE
GI Innovation To Evaluate GI-102 With KEYTRUDA In Resistant Cancers
26 Aug 2024 //
BUSINESSWIRE
Kineta Reopens VISTA-101 Trial For KVA12123 In Advanced Solid Tumors
19 Aug 2024 //
GLOBENEWSWIRE
Cue Biopharma Reports Q2 2024 Financial Results And Business Highlights
19 Aug 2024 //
GLOBENEWSWIRE
IO Biotech Reports Q2 2024 Results And Business Highlights
13 Aug 2024 //
GLOBENEWSWIRE
Prelude Therapeutics Reports Q2 2024 Results And Corporate Update
12 Aug 2024 //
GLOBENEWSWIRE
Two Ivonescimab Results For NSCLC To Be Presented At WCLC 2024
12 Aug 2024 //
PR NEWSWIRE
Merck Updates On KeyVibe-008 Trial In Small Cell Lung Cancer
09 Aug 2024 //
BIOSPACE
CG Oncology Reports Q2 2024 Results And Provides Business Updates
08 Aug 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Reports Q2 2024 Results And Business Highlights
08 Aug 2024 //
GLOBENEWSWIRE
PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024
05 Aug 2024 //
GLOBENEWSWIRE
Ultimovacs Announces FOCUS Phase II Trial Results For UV1
05 Aug 2024 //
GLOBENEWSWIRE
Medicenna Reports Q1 2025 Results And MDNA11 Complete Response
01 Aug 2024 //
GLOBENEWSWIRE
NextCure Reports Q2 2024 Results And Provides Business Update
01 Aug 2024 //
GLOBENEWSWIRE
Merus Reports Q2 2024 Results And Provides Business Update
01 Aug 2024 //
GLOBENEWSWIRE
Immutep Quarterly Activities Report Q4 FY24
31 Jul 2024 //
GLOBENEWSWIRE
CHMP Backs Merck`s KEYTRUDA Plus Padcev For First-Line Urothelial Cancer
26 Jul 2024 //
BUSINESSWIRE
Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev For UMUC
26 Jul 2024 //
BUSINESSWIRE
IO Biotech To Present Head And Neck Data At ESMO 2024
25 Jul 2024 //
GLOBENEWSWIRE
Adagene Reports H1 2024 Results And Provides Corporate Update
25 Jul 2024 //
GLOBENEWSWIRE
Bio-Thera Starts Integrated Trial For Keytruda Biosimilar BAT3306
25 Jul 2024 //
PR NEWSWIRE
Immutep Reports Successful FDA Meeting On Phase III NSCLC Trial Design
22 Jul 2024 //
GLOBENEWSWIRE
Immutep’s LAG-3 drug scores in Phase 2b head and neck cancer test
13 Jul 2024 //
PRESS RELEASE
Adagene To Present ADG126-Pembrolizumab Combo Data At ESMO Congress
12 Jul 2024 //
GLOBENEWSWIRE
Immutep Reports Positive Results In First Line Head And Neck Cancer
11 Jul 2024 //
GLOBENEWSWIRE
TuHURA Biosciences Gets Rights To Kineta`s KVA12123 Anti-VISTA Inhibitor
08 Jul 2024 //
PR NEWSWIRE
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study
08 Jul 2024 //
GLOBENEWSWIRE
Genentech Updates On Phase II/III SKYSCRAPER-06 Study In Lung Cancer
04 Jul 2024 //
BUSINESSWIRE
Roche to halt trial in latest setback for lung cancer immunotherapy
04 Jul 2024 //
REUTERS
Immutep To Present Clinical Results At ESMO Virtual Plenary And Host Webcast
03 Jul 2024 //
GLOBENEWSWIRE
New Efficacy Data for Non-Clear Cell RCC a From KEYNOTE-B61 Added to LENVIMA
27 Jun 2024 //
PR NEWSWIRE
Medicenna Announces EMA Approval of its Clinical Trial Application
26 Jun 2024 //
GLOBENEWSWIRE
Precision-Panc Team Opens PRIMUS-006 Study For Gemcitabine, Pembrolizumab
18 Jun 2024 //
GLOBENEWSWIRE
Merck Sharp Dohme Biologic Pembrolizumab Receives Suppl Approval in US
17 Jun 2024 //
FDA
FDA Approves Merck’s KEYTRUDA® For Endometrial Carcinoma
17 Jun 2024 //
BUSINESSWIRE
Zumutor Biologics Doses First Patient With Anti LLT1 Antibody
12 Jun 2024 //
PR NEWSWIRE
Ultimovacs provides update from Phase I study in malignant melanoma
11 Jun 2024 //
GLOBENEWSWIRE
Merck Sharp Dohme Biologic Pembrolizumab Receives Approval in US
07 Jun 2024 //
FDA
CG Oncology Announces Publication Of CORE-001 Study In Nature Medicine
06 Jun 2024 //
GLOBENEWSWIRE
Merck CMO talks Akeso, Summit`s Keytruda head-to-head win
04 Jun 2024 //
FIERCE PHARMA
HOOKIPA Pharma: Updated Phase 2 Oncology Data At ASCO 2024 Meeting
04 Jun 2024 //
GLOBENEWSWIRE
Moderna, Merck`s mRNA-4157 Plus Keytruda Shows Sustained RFS, DMFS Benefit
03 Jun 2024 //
ACCESSWIRE
Merus` MCLA-145 Mono/Combo Data In Solid Tumors At ASCO 2024
02 Jun 2024 //
GLOBENEWSWIRE
Immutep, Merck Collaborate On Efti Plus KEYTRUDA In Pivotal Phase III
02 Jun 2024 //
GLOBENEWSWIRE
Werewolf`s WTX-124 Mono/Combo Data In Solid Tumors At ASCO
01 Jun 2024 //
GLOBENEWSWIRE
Olomorasib KRAS G12C Data In Advanced Solid Tumors At ASCO 2024
01 Jun 2024 //
PR NEWSWIRE
TiumBio`s TU2218 Plus Pembro Phase 1b Interim Results At ASCO 2024
01 Jun 2024 //
PR NEWSWIRE
Acasunlimab Plus Pembro Shows Activity In Pretreated Metastatic NSCLC
01 Jun 2024 //
GLOBENEWSWIRE
NextCure Presents NC410-Pembrolizumab Combo Data At ASCO 2024
30 May 2024 //
GLOBENEWSWIRE
Ivonescimab Beats Pembrolizumab In PFS For PD-L1 Positive NSCLC China
30 May 2024 //
BUSINESSWIRE
FDA Grants Priority Review For Keytruda-Chemo In Mesothelioma
29 May 2024 //
BUSINESSWIRE
Merck nears $1.3 bln cash deal for eye-drug company EyeBio, WSJ reports
29 May 2024 //
REUTERS
ASCO 2024: Rakuten’s photoimmunotherapy & Keytruda combo shows efficacy in HNSCC
28 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Keytruda extends survival in high-risk triple negative breast cancer
28 May 2024 //
PRESS RELEASE